Abstract
More is not always better: Until now it was considered that modulators of P-glycoprotein-associated multidrug resistance in cancer treatment showed greater inhibitory activity with an increasing number of moieties that could participate in hydrogen bonds. This theory has been questioned for the first time with a new class of symmetrical inhibitors 1 based on hydroxymethyl-3,9-diazatetraasteranes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
